Form ABS-15G Centra Funding, LLC For: Dec 31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM ABS-15G
ASSET-BACKED SECURITIZER
REPORT PURSUANT TO SECTION 15G OF
THE SECURITIES EXCHANGE ACT OF 1934
Check the appropriate box to indicate the filing obligation to which this form is intended to satisfy:
☒ | Rule 15Ga-1 under the Exchange Act (17 CFR 240.15Ga-1) for the reporting period January 1, 2022 to December 31, 2022 |
Date of Report (Date of earliest event reported): January 27, 2023
Centra Funding, LLC1
Commission File Number of securitizer:
Central Index Key Number of securitizer: 0001806577
Jay Libowitz, Phone: (888) 779-4629 Ext. 136
Name and telephone number, including area code, of the person to contact in connection with this filing.
Indicate by check mark whether the securitizer has no activity to report for the initial period pursuant to Rule 15Ga-1(c)(1) ☐
Indicate by check mark whether the securitizer has no activity to report for the quarterly period pursuant to Rule 15Ga-1(c)(2)(i) ☐
Indicate by check mark whether the securitizer has no activity to report for the annual period pursuant to Rule 15Ga-1(c)(2)(ii) ☒
1 | Centra Funding, LLC, as securitizer, is filing this Form ABS-15G in respect of all asset-backed securities outstanding during the reporting period, including asset-backed securities privately issued by an affiliated entity. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the reporting entity has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Centra Funding, LLC (Securitizer) | ||
By: | /s/ Jay Libowitz | |
Name: Jay Libowitz | ||
Title: Treasurer |
Date: January 27, 2023
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Spinergie's digital fleet management platform selected by Seaward Services for remote monitoring and performance optimization
- AGILITI ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of AGTI and Encourages Investors to Contact the Firm
- FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!